2015
DOI: 10.1016/j.bmc.2015.06.022
|View full text |Cite
|
Sign up to set email alerts
|

Intriguing possibilities and beneficial aspects of transporter-conscious drug design

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
29
0

Year Published

2015
2015
2020
2020

Publication Types

Select...
7
2

Relationship

3
6

Authors

Journals

citations
Cited by 27 publications
(29 citation statements)
references
References 85 publications
(102 reference statements)
0
29
0
Order By: Relevance
“…Accordingly, transporter-conscious drug design is an excellent tactic for effective cancer chemotherapy and good ADMET. In design of compounds transported by arbitrary SLC transporters, incorporated structural commonality of their substrates into designed compounds act as transporter recognition unit [3]. Compounds possessing peptide mimic as transporter recognition unit may enter into cancer cells overexpressing PEPT1.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Accordingly, transporter-conscious drug design is an excellent tactic for effective cancer chemotherapy and good ADMET. In design of compounds transported by arbitrary SLC transporters, incorporated structural commonality of their substrates into designed compounds act as transporter recognition unit [3]. Compounds possessing peptide mimic as transporter recognition unit may enter into cancer cells overexpressing PEPT1.…”
Section: Discussionmentioning
confidence: 99%
“…Therefore, the use of their transport systems overcomes the problems such as drug permeability into cancer cells and drug resistance through the overexpression of MDR1 (Figure 1) [1,2]. I have already described intriguing possibilities and beneficial aspects of transporter-conscious drug design [3]. In this review, I will introduce the effective method of cancer chemotherapy based on transporter-conscious drug design.…”
Section: Introductionmentioning
confidence: 99%
“…Certain N-containing compounds such as diphenhydramine and morphine are the substrates of the proton-coupled organic cation (H + /OC) antiporter, although its amino acid sequence and its topology have not been identified. 2,3) Thus, drugs designed based on such transporters, that is, transporterconsciously designed drugs, can be transported into the brain using SLC transporters expressed at the BBB. 4) In contrast, high-and middle-molecular compounds are too large to be transported by the transporters.…”
Section: Introductionmentioning
confidence: 99%
“…Furthermore, receptor-mediated transcytosis (RMT) distributes the corresponding middleor high-molecular-weight ligands, such as insulin and transferrin, across the capillary endothelium to the brain. Therefore, carrier-mediated transport using arbitrary substrates with cargos could be a direct approach to bypass MDR1 and the tight junction-based physical boundary at the BBB [3]. Similarly, RMT using arbitrary ligands with cargos could be a direct approach to bypass tight junction-based boundary at the BBB [3].…”
Section: Introductionmentioning
confidence: 99%